High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome (Q36975872)

17 August 2017

1 reference

title

High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome (English)

1 reference

17 August 2017

0 references

1 reference

Christopher P Cannon

1

1 reference

17 August 2017

1 January 2007

1 reference

17 August 2017

1 reference

17 August 2017

8 Suppl 6

1 reference

17 August 2017

S14-23

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

17 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

The forgotten majority: unfinished business in cardiovascular risk reduction

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

High-density lipoprotein subfractions and risk of coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Clinical significance of high-density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate-binding cassette protein A1 transporter

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

What is the most effective strategy for managing diabetic dyslipidaemia?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Pharmacotherapy to reduce visceral fat.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

The metabolic syndrome, hyperlipidemia, and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Hypolipidemic therapy for the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

New and emerging strategies for reducing cardiometabolic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Metabolic abnormalities: high-density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

HDL: the 'new' target of cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Cardioprotection with high-density lipoproteins: fact or fiction?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Metabolic syndrome aggravates the increased endothelial activation and low-grade inflammation in subjects with familial low HDL.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

High-density lipoprotein restores endothelial function in hypercholesterolemic men.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

HDL stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Serum high-density lipoprotein-cholesterol levels modify the association between plasma levels of oxidatively modified low-density lipoprotein and coronary artery disease in men.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

C-reactive protein levels and outcomes after statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

High-density lipoproteins and endothelial function

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention. A lesson from cholesterol turnover studies and others

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Cholesterol: the good, the bad, and the stopped trials

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Nonpharmacologic management of low levels of high-density lipoprotein cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980011-1

7 January 2021

10.1016/S1098-3597(07)80011-1

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17948363